Alumis (ALMS) is down -16.1%, or -$3.99 to $20.81.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
- Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
- Alumis price target raised to $55 from $50 at Oppenheimer
- Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
- Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission